Kiniksa Pharmaceuticals International, plc

KNSA

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Baker Bros. Advisors OrbiMed Advisors Driehaus Capital

Catalysts

No catalysts tracked.

Activist Filings

SC 13D/ABaker Bros. Advisors9.2%Jul 28, 2020

SC 13D/ABaker Bros. Advisors11.4%May 18, 2020

SC 13D/A

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 2,826,246Value: $116.6M

## Signal Note: Baker Bros. Initiates Large Position in Kiniksa (KNSA) **Note: The reported position value of ~$116.6B appears to be a data error — 2.83M shares at recent prices (~$41) would represent ~$116M, which is the plausible figure and still a significant conviction bet.** Baker Bros. building a new ~$116M position in Kiniksa is a high-conviction signal given their concentrated, specialist approach. KNSA's lead asset is **rilonacept (Arcalyst)**, an IL-1 inhibitor already FDA-approved for **recurrent pericarditis**, which is generating accelerating revenue (~$100M+ annual run rate) with significant commercial upside as diagnosis rates improve in a historically underdiagnosed condition. The timing likely reflects Baker's view that the market is underpricing Arcalyst's peak

OrbiMed AdvisorsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ARGX3 funds PRAX3 funds EWTX3 funds CELC3 funds INSM3 funds JBIO3 funds RVMD3 funds RYTM

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: OrbiMed Initiates $7.7M Position in Kiniksa OrbiMed's new $7.7M stake in KNSA suggests conviction in the company's pipeline, likely driven by ARCALYST (rilonacept) commercial traction in rare inflammatory conditions or upcoming catalysts around pipeline advancement. Kiniksa's market cap is modest (~$400-500M range), making this a meaningful allocation that warrants monitoring of upcoming clinical readouts or revenue guidance updates.